2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1
2
Phase 4
1
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Cisplatin
726
Carboplatin
609
Paclitaxel
579
Cyclophosphamide
516
Radiotherapy
511
Docetaxel
477
Fluorouracil
454
Gemcitabine
438
Doxorubicin
383
Capecitabine
361
Dexamethasone
328
Oxaliplatin
289
pembrolizumab
283
Leucovorin
283
Bevacizumab
275
Etoposide
272
Vincristine
270
Rituximab
246
Prednisone
223
Pemetrexed
217
Cytarabine
205
Drug Therapy
194
Trastuzumab
176
Irinotecan
174
Methotrexate
171
Lenalidomide
137
Nivolumab
136
Filgrastim
135
Epirubicin
129
Tamoxifen
128
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled